Multiple sclerosis and depression;Esclerosis múltiple y depresión

Revista de Neurologia

Volumn 38, Issue 6, 2004, Pages 524-529

  Sanchez Lopez M P ^a   Olivares Perez T ^a   Nieto Barco, A ^a   Hernandez Perez M A ^b   Barroso Ribal, José ^a,c  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c Campus Universitario de Guajara   (Spain)

Author keywords

Depression; Disability; Interferon; Multiple sclerosis; Neuropsychology; Processing speed

Indexed keywords

IMMUNOMODULATING AGENT; INTERFERON;

ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; EMOTION; FEMALE; HUMAN; IMMUNOMODULATION; INFORMATION PROCESSING; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PHYSICAL DISABILITY; PREVALENCE; SCORING SYSTEM; TASK PERFORMANCE; TREATMENT OUTCOME; VELOCITY; ADULT; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADULT; DEPRESSION; FEMALE; HUMANS; INTERFERONS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS;

EID: 2142763092     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3806.2003543     Document Type: Article

References (39)

1. Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus others symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc 1995; 1: 291-6.
2. Minden SL. Mood disorders in multiple sclerosis: diagnosis and treatment. J Neurovirol 2000; 6: 160-7.
3. Mohr DC, Goodkin DE, Likosky W, Beutler L, Gatto N Langan MK. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med 1997; 20: 407-14.
4. Nyenhuis DL, Luchetta T, Yamamoto C, Terrien A, Bernardin L, Rao SM, et al. The development, standardisation and initial validation of the Chicago Multiscale Depression Inventory. J Pers Assess 1998; 70: 386-401.
5. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-3.
6. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psych 1987; 9: 426-34.
7. Stenager EN, Stenager E, Koch-Henricksen N, Bronnum-Hansen H, Hyllested K, Jensen K, et al. Suicide and multiple sclerosis: an epidemiological investigation. Neurol Neurosurg Psychiatry 1992; 55: 542-5.
8. Lewinson PM, Hoberman H, Teri L, Hautzinger M. An integrative theory of depression. In Reiss S, Bootzin RR, eds. Theoretical issues in behavior therapy. San Diego, CA: Academic Press; 1985. p. 331-59.
9. Voss WD, Arnett PA, Higginson CI, Randolph JJ, Campos MD, Dick DG. Contributing factors to depressed mood in multiple sclerosis. Arch Clin Neuropsychol 2002; 17: 103-15.
10. Ritvo PG, Fisk JD, Archibald CJ, Murray TJ, Field C. Psychosocial and neurological predictors of mental health in multiple sclerosis patients. J Clin Epidemiol 1996; 49: 467-72.
11. Fisher JS, Foley FW, Aikens JE, Ericson D, Rao SM, Shindell S. What do we really know about cognitive dysfunction, affective disorders, and stress in multiple sclerosis? A practitioner's guide. J Neurol Rehab 1994; 8: 151-64.
12. Sánchez MP, Olivares T, Nieto A, Wollmann T, Hernández MA, Barroso J. Effect of multiple sclerosis treatment with interferon beta 1b and interferon beta 1a (Rebif) on the depressive symptomatology [abstract]. J Neurol 2002; 249: 206.
13. Arnett PA, Higginson CI, Randolph JJ. Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 2001; 7: 665-74.
14. Daly E, Komaroff AL, Bloomingdale K, Wilson S, Albert MS. Neuropsychological function in patients with chronic fatigue syndrome, multiple sclerosis and depression. Appl Neuropsychol 2001; 8: 12-22.
15. Maor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients-the role of depression. Mult Scler 2001; 7: 131-5.
16. Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy and amyotrophic lateral sclerosis. Arch Neurol 1984; 41: 1067-9.
17. Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med 1989; 19: 887-95.
18. Fassbender K, Schmidt R, Mossner R, Kischka U, Fuhnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 1998; 55: 66-72.
19. Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 1992; 49: 23844.
20. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonespecific and antigen-specific Th 1 responses in multiple sclerosis. Arch Neurol 2001; 58: 1081-6.
21. Pujol J, Bello J, Deus J, Cardoner N, Marti-Vilalta JL, Capdevila A. Beck Depression Inventory factors related to demyelinating lesions of the left arcuate fasciculus region. Psych Res 2000: 151-9.
22. Neilley LK, Goodkin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta 1b in MS: results of an open label trial. Neurology 1996; 46: 552-4.
23. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
24. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, Van der Wende J, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta 1a. Mult Scler 1998; 4: 487-9.
25. Borrás C, Río J, Porcel J, Barrios M, Tintoré M, Montalbán X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology 1999; 52: 1636-9.
26. Mohr DC, Likosky W, Dwyer P, Van der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon Beta-1a treatment for multiple sclerosis. Arch Neurol 1999; 56: 1263-5.
27. Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7: 243-8.
28. Feinstein A. Multiple Sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler 2000; 6: 343-8.
29. Poser CM, Paty DW, Scheinberg L, McDonald, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
30. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
31. Beck AT, Ward CH, Mendelson M, Mock I, Erbaugh I. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 53-63.
32. Conde V, Franch JI. Escalas de evaluación comportamental para la cuantificación de la sintomatología psicopatológica en los trastornos angustiosos y depresivos. Madrid: Upjohn; 1984.
33. Beck AT, Lester D. Components of depression in attempted suicides. J Psychol 1973; 85: 257-60.
34. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
35. Schuhfried G. Vienna Reaction Unit (manual). Austria: Schuhfried; 1992.
36. SPSS. Base para Windows, v. 10.0.5. Guía del usuario. Chicago: SPSS; 1999.
37. Pliskin NH, Hammer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon B-1b. Neurology 1996; 47: 1463-8.
38. Barak Y, Achiron A. Effect of interferon beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47: 11-4.
39. Fisher JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000; 48: 885-92.